Transmitted multidrug resistant HIV-1: New and investigational therapeutic approaches

Current Opinion in Investigational Drugs

Volumn 7, Issue 8, 2006, Pages 709-720

  Shet, Anita ^a   Markowitz, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Investigational antiretroviral agents; Multidrug resistant HIV 1; Therapeatic approach; Transmission

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; AMD 070; ANTIVIRUS AGENT; APLAVIROC; AVX 754; BEVIRIMAT; CD4 IMMUNOGLOBULIN G2; DARUNAVIR; DELAVIRDINE; DEXELVUCITABINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; JTK 303; MARAVIROC; MK 0518; NEVIRAPINE; PLACEBO; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG STRUCTURE; FATIGUE; FLATULENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFECTION RATE; INFECTION RISK; INJECTION SITE BLEEDING; INSOMNIA; LIFE CYCLE; LIVER TOXICITY; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; NAUSEA; NOSE CONGESTION; PHARYNGITIS; PHENOTYPE; PREVALENCE; PRURITUS; REVIEW; RHINITIS; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; URTICARIA; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTEGRASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33747617818     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. UNAIDS/WHO AIDS Epidemic update: UNAIDS, Geneva, Switzerland (2005). http.//www.unaids.org/epi/2OO5/doc/report_pdf.asp
2. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO: Time trends in primary HIV-1 drug resistance among recently infected persons. J Am Med Assoc (2002) 288(2):181-188.
3. Little SJ, Hotta S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M et al: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 347(6):385-394.
4. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M: Tracking the prevalence of transmitted antiretroviral drug resistant HIV-1 in Now York City: A decade of experience. J Acquir Immune Defic Syndr (2006) 41(4):439-446.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271(5255):1582-1586.
6. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD: A novel antiviral Intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 77(8):5037-5038.
7. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science (1995) 287(5197):483-489.
8. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr (2000) 23(5):386-395.
9. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J: Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 13(13):1763-1769.
10. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 15(15):4040-4049.
11. Goudsmit J, de Ronde A, de Rooij E, de Boer R: Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol (1997) 71(8):4479-4484.
12. Mammano F, Petit C, Clavel F: Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protesse and gag coevolution in protease inhibitor-treated patients. J Virol (1998) 72(9):7632-7637.
13. Martinez-Picado J, Savera AV, Sutton L, D'Aquila RT: Replicative fitness of protease Inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol (1999) 73(5):3744-3752.
14. Devereux HL, Emery VC, Johnson MA, Loveday C: Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol (2001) 65(2):218-224.
15. Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M: Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol (2003) 69(1):1-6.
16. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 13(17):2349-2359.
17. Simon V, Padte N, Murray D, Vanderhoeven J, Wrin T, Parkin N, Di Mascio M, Markowitz M: Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol (2003) 77(14):7736-7745.
18. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP: Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 71(9):6662-6670.
19. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Gonway B, Lalonde R, Sekaly RP et al: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 76(4):1753-1761.
20. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F: Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients falling antiretioviral therapy. J Virol (2001) 75(14):6410-6417.
21. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 18(12):1683-1689.
22. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V: Persistence of multidrug-resistant HIV-1 without antirstroviral treatment 2 years after sexual transmission. Antvir Ther (2004) 9(3):415-421.
23. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 344(7):472-480,
24. Devereux HL, Youle M, Johnson MA, Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 13(18):F123-F127.
25. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Am Med Assoc (2000) 283(18):2417-2426.
26. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA: Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis (1997) 175(6):1502-1506.
27. Hecht FM, Grant RM, Petropoulos; CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med (1998) 339(5):307-311.
28. Desai N, Mathur M: Selective transmission of multidrug resistant HIV to a newborn related to poor maternal adherence. Sex Transm Infect (2003) 79(5):419-421.
29. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, La Mar M et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet (2005) 366(9464):1031-1038.
30. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA: The prevalence of antirstroviral drug resistance in the United States. AIDS (2004) 18(10):1393-1401.
31. Weinstock HS, Zaid I, Heneine W, Bennett D, Garda-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D et al: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 189(12):2174-2180.
32. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C et al. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ (2005) 331(7529):1368.
33. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Baloda C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I et al: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis (2005) 192(6):958-968.
34. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med (2001) 7(9):1016-1020.
35. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dfs (2003) 187(4):683-686.
36. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A: Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol (2001) 76(7):3291-300.
37. AIDSinfo clinical guidelines. US Department of Health and Human Services - AIDSinfo, Rockville, MD, USA (2005). http://www.aidsinfo.nih.gov/Guidelines/
38. Deeks SG, Hoh R, Neilands TB, Liegier T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN: Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis (2005) 192(9):1537-1544.
39. Castagna A, Denise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cemuschi M, Hasson H, Clementi M et al Lamivudine monatherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS (2006) 20(6):795-803.
40. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA et al. Dual vs single protease, inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc (2002) 288(2):169-180.
41. US Food and Drug Administration: Drugs used in the treatment of HIV infection. Food and Drug Administration, Rockville, MA, USA (2005). http://www.fda.gov/oashi/aids/virals.html
42. Lalezari JP, Henry K, O'Heam M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 348(22):2175-2185.
43. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L et al: Efficacy of entuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 348(22):2186-2195.
44. Montaner J, Chung J, Guimaraes D, DeMasi R, Gafoor Z, Salgo M: A treatment staging proposal derived from a post-hoc analysis of the 48 week results from the TORO studies. International AIDS Conference (2004) 15:Abs TuPeB4483.
45. Larder BA, Hertogs K Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth VWV, Tarpley G: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14(13):1943-1948.
46. Schapiro J, Cahn P, Trottier B, Antunes F, Jayaweera D, Gerstoft J Norris D, Cooper D, Hicks C, McCallister S, Hall D et al. Effect of baseline genotype on response to tipranavir/ritonovir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: The phase 3 RESIST-1 and -2 trials. Conference on Retroviruses and Opportunistic Infections (2005) 12:Abs 104.
47. Walmsley S, Leith J, Katiama C, Arasteh K, Pierone G, Blick G, Lazzarin A, Johnson M, Samuels C, Jones P, Chaves R et al: Pharmcokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV). Interim analysis of Bl1182.51. International AIDS Conference (2004) 15:Abs WeOrB1236.
48. Cahn P, Lange J, Cassetti I, Sawyer J, Zala C, Rolon M, Bologna R, Shiveley L: Anti HIV-1 activity of SPD754 a now NRTI: Results of a 10 day monotherapy study in treatment naïve HIV patients. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, (2003):Abs LB15.
49. Cahn P, Van Leeuwen R, Sawyer J, Shiveley L: Tolerability and anti HiV-1 activity of SPD764 in 10 days monotherapy in treatment naive patients. ICAAC (2003) 4:Abs H-869.
50. Cohen C, Katlama C, Murphy R, Gathe J, Brinson C, Richmond G, Girard P-M, Fessel J, Liappis A, Puglia E, Rodwick B et al: Antiretroviral activity and tolerability of Reverset (D-d4FC), a new fluoro-cytidine nucleoside analog when used in combination therapy in treatment-experienced patients: Results of phase IIb study RVT-203. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio do Janeiro, Brazil (2005):Abs WeOaLB0103.
51. Vingerhoets, J, Azijn H, Fransen E, De Beare I, Smeulders L, Jochmans D, Andries K Pauwels R, de Bethune MP: TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vhm selection experiments. J Viral (2005) 79(20):12773-12782.
52. Vingerhoets J, Peeters M, Corbett C, Iveson K, Vandermeulen K, Keen R, Woodfall B, De Béthune MP: Effect of baseline resistance on the virological response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: Analysis of study TMC125-C223. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 154.
53. Tibotec Pharmaceuticals Ltd: Tibotec discontinues exploratory trial with TMC125. Press Release (2005): November 29.
54. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stabbing J, vant Klooster GA et al: An open-label assessment of TMC 125 - a new, next generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS (2003) 17(18):F49-F54.
55. Tiboteo-Virco NV. Next generation NNRTI, TMC125 shovis antiviral effect in patients failing HIV therapy. Press Release (2002): February 28.
56. Gazzard B, Pozniak K, Arasteh K Staszewski S, Rozenbaurn W, Yeni P, van't Klooster G, De Dier K Peeters M, de Bethune MP, Graham N, Pauwels R: TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-expertenced HIV-infected individuals. Conference on Retroviruses and Opportunistic Infections (2002) 9: Abs 4.
57. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wgerinck P, de Bethune MP: TMC114, a novel human immunodeficiency virus type 1 protease, inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother (2005) 49(6):2314-2321.
58. Arasteh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peelers M, Rinehart A, Lefebvre E: TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive andretroviral regimen: A 14-day proof-of-principle trial. AIDS (2005) 19(9):943-947.
59. Wilkin T, Haubrich R, Steinhart CR: TMCI 14/r superior to standard of care in 3-class-experienced patients: 24-Wks primary analysis of the Power 2 study (C202). ICAAC (2005) 45:Abs H-413.
60. De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, Van Baelen B, De Paepe E, Vangeneugden T, Lefebvre E, De Béthune MP: Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: Preliminary analysis of data from PI-experienced patients from Power 1 and Power 2. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 157.
61. Ortho Biotech Inc: FDA approves new HIV treatment for patients who do not respond to existing drugs. Press Release (2006): June 23.
62. Roche Holding AG: US FDA approval of boosted protease inhibitor enables potent new HIV drug combination with Fuzeon. Press Release (2006): June 23.
63. Tibotec Pharmaceuticals Ltd: Prezista receives US FDA approval as part of HIV combination therapy. Press Release (2006): June 23.
64. Berger DS, Bellos N, Farthing C, Stryker R, Colson A, Pierone G, Lefebvre E, Cefalone M, Koester A, van Baelen K, de Pauw M: TMC114/r in 3-class-experienced patients: 24-Wk primary safety analysis of the Power 2 study (C202). ICAAC (2005) 46Abs H-1094.
65. Roche Holding AG: Investigational boosted protease, inhibitor, TMC114, works better in combination with Fuzoon. Press Release (2005): December 20.
66. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans, RM: Combination of protease inhibitors far the treatment of HIV-1-infected patients: A review of pharmacolkinetics and clinical experience. Antivir Ther (2001) 6(4)-201-229.
67. Pommier Y, Johnson AA, Marchand C: Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov (2005) 4(3):236-248.
68. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R: Patent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Conference on Retroviruses and Opportunistic Infections (2006) 13Abs 159LB.
69. Merck & Co Inc: Results of an initial phase II study showed that MK-0518, an investigational integrase inhibitor, provided superior reduction in HIV viral RNA versus placebo in treatment-naïve HIV-infected patients. Press Release (2005): November 18.
70. Ramirez JO, Teppler H, Kovacs C, Steigbigel RT, Cooper D, Liporace RL, Schwartz R, Wenning L, Zhao J, Gilde L, Isaacs R, Nguyen B-Y: Antiretroviral effect of MK-0518, a novell HIV-1 integrase inhibitor, in ART-naïve HIV4-infected patients. Eur AIDS Clin Soc (2005) 10:Abs LBPS1/6.
71. Merck & Co Inc: Merck announces interim results from phase II study of MK-0518, an investigational oral HIV integrass, inhibitor. Press Release (2006): February 09.
72. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Cheng A, Kearney B: The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 160LB.
73. Moore JP, Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA (2003) 100(19):10598-10602.
74. Hanna G, Lalezari J, Hellinger J, Wohl D, Masterson T, Fiske W, Kadow J, Lin P, Giordano M, Colonno R, Grasela D: Antiviral activity, safety and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. Conference on Retroviruses and Opportunistic Infections (2004) 11:Abs 141.
75. Bristol Myers Squibb Co: Bristol-Myers Squibb presents data providing proof-of-concept for novel experimental oral attachment inhibitor, a potential now class of antiretroviral therapy. Press Release (2004): February 11.
76. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA et al: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 48(2):423-429.
77. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF 3rd, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 69(11):6809-6817.
78. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR Jr: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis (2004) 189(2):286-291.
79. Norris D, Morales J, Gathe J, Godofsky E, Garcia F, Hardwicke R, Jackson J, Lewis S, Paradiso L: TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity then OBR alone in HIV-treatment experienced patients. ICAAC (2005) 45:Abs LB2-26.
80. Tanox Inc: Tanox reports 48-week results from TNX-355 phase 2 clinical trial. Press Release (2006): May 02.
81. Tanox Inc: New research reaffirms tropism independence of TNX-355; Data for Tanox's novel HIV viral entry inhibitor presented at 2008 CROI. Press Release (2006): February 09.
82. Pfizer Inc: Phase 1/2a study results indicate maraviroc well-tolerated in doses up to 300 mg twice-daily. Press Release (2005): July 26.
83. Perros M: Inhibitors of HIV entry targeting CCR5. International Conference on Antiviral Research (2005) 18:Plenary presentation.
84. Russell D, Bakhtyari A, Jazrawi RP, Whitlock L, Ridgway C, Michale M, Abel S: Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300 mg) bid for 28 days in healthy males and females. ICAAC (2003) 43:Abs H-874.
85. Steel H: Special presentation on aplaviroc-related hepatotoxicky. Tenth European AIDS Conference, Dublin, Ireland, UK (2005).
86. Liver toxicity case seen with CCR5 antagonist maraviroc. Clinical Care Options, Reston, VA, USA (2005). http://www.cliniclcareoptions.com/HIV/Conference%2OCoverage/ Dublin%202005/News/news_dublin2005_5.aspx
87. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM et al. Efficacy of short-term monotherapy with maraviroc, a now CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 11(11):1170-1172.
88. Schurmann D, Rouzier R, Nougarede R, Reynes J, Fatkenheuer G, Raffi F, Michelet C, Tarral A, Hoffmann C, Kiunke J, Sprenger H et al: SCH D: antiviral activity of a CCR5 receptor antagonist. Conference on Retroviruses and Opportunistic Infections (2004) 11:Abs 140LB.
89. Greaves G, Landovitz R, Fatkenheuer G, Hoffmann C, Antunes F, Angel J, Boparai N, Knepp D, Keung A, Dunkie L: Late virologic breakthrough in treatment-naïve patients on a regimen of Combivir + vicriviroc. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 161LB.
90. Stone N, Dunaway S, Flexner C, Calandra G, Wiggins I, Conley J, Snyder S, Tiemey C, Hendrix W. Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects. International AIDS Conference (2004) 15:Abs TuPeB4475.
91. AnorMED Inc: AnorMED initiates enrollment into phase I/II study for new HIV entry inhibitor. Press Release (2005): March 16.
92. Needle-free Fuzeon in works. AIDS Patient Care STDS (2005) 19(9):614-616.
93. Delmedico M, Bray B, Cammack N, Davison D, Dwyer J, Frick L, Tvermoes N, Wring S, Zhang H, Greenberg M: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 48.
94. Roche AG/Trimeris Inc: Positive pro-clinical data on two now Investigational HIV fusion inhibitors presented at major scientific meeting. Press Release (2006): February 09.
95. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP et al: PA457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Aced Sci USA (2003) 100(23):13555-13560.
96. Beatty G, Lalezari J, Eron JJ Jr. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. ICAAC (2005) 45:Abs H-416d.
97. Smith P, Forrest A, Beatty G, Jacobson J, Lalezari J, Eron J, Pollard R, Saag M, Doto J, Martin D: Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 52.
98. Progenies Pharmaceuticals Inc: Progenies reports positive results from phase 1 clinical trial of PRO 140, a novel monoclonal antibody that blocks HIV entry; single dose coats immune cells for two months, potential long-acting HIV therapy. Press Release (2005): September 09.
99. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD: Update of the drug resistance mutations in HIV-1: Fall 2005. Topics in HIV Med (2005) 13(4):125-131.